CRIS Current Research Information System

DE ROSA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.359
EU - Europa 1.148
AS - Asia 586
AF - Africa 69
SA - Sud America 3
OC - Oceania 2
Totale 3.167
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.349
GB - Regno Unito 277
IT - Italia 274
CN - Cina 220
VN - Vietnam 162
SE - Svezia 144
DE - Germania 108
SG - Singapore 106
IN - India 63
RU - Federazione Russa 63
IE - Irlanda 58
CH - Svizzera 53
FR - Francia 45
TG - Togo 29
UA - Ucraina 28
ZA - Sudafrica 27
FI - Finlandia 23
EE - Estonia 18
BG - Bulgaria 16
JO - Giordania 15
BE - Belgio 11
NL - Olanda 8
CA - Canada 6
CI - Costa d'Avorio 6
IR - Iran 6
NG - Nigeria 5
AT - Austria 4
NI - Nicaragua 4
GR - Grecia 3
ID - Indonesia 3
MY - Malesia 3
PL - Polonia 3
RO - Romania 3
AU - Australia 2
CL - Cile 2
ES - Italia 2
HK - Hong Kong 2
LB - Libano 2
BR - Brasile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
HR - Croazia 1
HU - Ungheria 1
KR - Corea 1
LT - Lituania 1
LU - Lussemburgo 1
PH - Filippine 1
PT - Portogallo 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 3.167
Salva come PNG Salva come JPEG
Città #
Southend 260
Chandler 188
Dong Ket 162
Santa Clara 113
Ashburn 98
Singapore 96
Fairfield 95
Princeton 72
Wilmington 65
Dublin 58
Houston 54
Bern 49
Ann Arbor 45
New York 45
Woodbridge 41
Bologna 36
Seattle 33
Boardman 30
Lomé 29
Westminster 28
Nanjing 27
Padova 27
Cambridge 26
Helsinki 23
Medford 23
Jinan 21
Shenyang 18
Milan 16
Rome 16
Saint Petersburg 16
Sofia 16
Amman 15
Beijing 14
Mülheim 14
Turin 14
Berlin 12
San Diego 12
Brussels 11
Hebei 11
Changsha 10
Florence 9
Jacksonville 9
Mountain View 9
Pune 9
Jiaxing 8
Ravenna 8
Tianjin 8
Fremont 7
Guangzhou 7
Redwood City 7
Abidjan 6
Nanchang 6
Torino 6
Abeokuta 5
Dearborn 5
Kuban 5
Monmouth Junction 5
Norwalk 5
Shanghai 5
Taizhou 5
Toronto 5
Ardabil 4
Bari 4
Falls Church 4
Lanzhou 4
Managua 4
Mumbai 4
Wuhan 4
Castelfranco Emilia 3
Forlì 3
Haikou 3
Kunming 3
Los Angeles 3
Ningbo 3
Phoenix 3
San Mateo 3
San Venanzo 3
Taiyuan 3
Xi'an 3
Zhengzhou 3
Bühl 2
Cinisello Balsamo 2
Des Moines 2
Empoli 2
Gallipoli 2
Genoa 2
Hangzhou 2
Hefei 2
Kilburn 2
Langfang 2
Lausanne 2
London 2
Luzzara 2
Manduria 2
Monza 2
Olalla 2
Parma 2
Pastrengo 2
Pekanbaru 2
Piacenza 2
Totale 2.182
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 307
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 196
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 187
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 174
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 149
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 117
High prevalence of asbestos exposure in bile duct cancer patients 115
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 113
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 111
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 111
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 109
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 108
Irinotecan toxicity: genes or intestinal microflora? 107
KRAS and BRAF mutational status as selective criteria for targeted therapy in cholangiocarcinoma. 106
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. 103
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 98
Second-line chemotherapy in biliary tract cancer patients. 96
Second-line chemotherapy in patients with biliary tract cancer. 94
Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study. 93
The follow-up issues: from the necessity to the opportunity 92
High-resolution genomic profiling of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients identified novel recurrent copy number variations involved in both pathogenesis and resistance to tyrosine kinase inhibitors 89
Feasibility of triplets (5-FU, oxaliplatin and irinotecan based) in front and subsequent lines of metastatic colorectal cancer patients. 86
Genome wide analysis of Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) reveals a recurring deletion of VPREB1 gene which affects B-cell differentiation 85
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR 83
METRONOMIC CAPECITABINE IN HEPATOCELLULAR CARCINOMA RELAPSE AFTER LIVER TRANSPLANTATION: A RETROSPECTIVE STUDY 81
Metronomic capecitabine as second-line treatment after sorafenib for hepatocelllular carcinoma. 80
Metronomic capecitabine in advanced hepatocellualr cacinoma patients who have failed sorafenib: a phase II study 79
Intestinal microbiota around colorectal cancer genesis 75
Totale 3.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.959
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.959
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020218 0 0 0 0 0 0 0 55 55 28 25 55
2020/2021369 66 14 6 9 3 14 11 21 43 7 7 168
2021/2022586 63 32 20 29 54 35 18 35 17 37 144 102
2022/2023750 85 111 39 89 44 54 10 47 114 22 75 60
2023/2024254 27 28 2 22 12 88 16 8 5 11 19 16
2024/2025493 35 88 59 63 156 28 39 25 0 0 0 0
Totale 3.244